Merus N.V. (MRUS) 30-day option implied volatility amid price movement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Francis Halzen wins Nobel physics prize for Antarctic 'ghost particle' hunt
Merus N.V. (MRUS) PT Raised to $84 at BMO Capital
May 28, 2024 11:51 AM EDTBMO Capital analyst Etzer Darout raised the price target on Merus N.V. (NASDAQ: MRUS) to $84.00 (from $58.00) while maintaining a Outperform rating.
The analyst comments "We're updating our model following MRUS's pre-ASCO petosemtamab plus pembrolizumab combination update in 1L head and neck cancers... More
BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)
May 28, 2024 8:13 AM EDTBMO Capital analyst Etzer Darout reiterated an Outperform rating and $58.00 price target on Merus N.V. (NASDAQ: MRUS).
The analyst comments "MRUS announced updated data from the Phase 1/2 trial evaluating petosemtamab/ pembrolizumab in 1L HNSCC patients, reporting a 67% ORR in 24 patients, including a 75%... More



